T.E.H.N.O.F.A.R.M. OS

What it is

The product is built around a single hardened terminal operating within a written, machine-readable constitution. The constitution defines what the system may recommend, what it must defer to a human, and where it must explicitly recognise its own limits. The terminal is not a diagnostic chatbot. It is not an autonomous AI doctor. It is an operating system for clinical behaviour in environments where the assumption of physician proximity does not hold.

Where it comes from

The product extends TEHNOFARM's thirty-three-year pharmaceutical, biotechnology, and information-technology mandate into a regulated software domain. The technical foundation rests on intellectual-property infrastructure developed by TF Intelligence Platform S.R.L., the software and IP entity of the TF Group.

Why now

Three conditions have aligned in recent years:

• Deep-space agencies have formally articulated the need for autonomous medical operations beyond Earth-contact latency.
• The World Health Organization has named antimicrobial resistance among its leading global threats, with primary-care prescription identified as a major contributor.
• The European Union's AI Act provides a clear regulatory frame for constitutionally bounded medical software.

T.E.H.N.O.F.A.R.M. OS is being designed in advance to meet these conditions.

Governance frame

The product operates under a written constitutional document and a public-facing operator oath. Together they define the boundaries within which the system functions and the accountability chain through which every clinical decision is reviewed. The governance frame is designed to satisfy medical, legal, insurance, and certification review. The specific constitutional text and oath wording are released under NDA to qualifying partners.

How accountability works

Every recommendation the system produces carries a cryptographic provenance trail. Every decision contemplated in the absence of a physician is automatically queued for retrospective review by a licensed physician once medical contact is restored. The product does not replace the physician. It ensures that no period of patient care — however isolated — exists outside the chain of medical accountability.

Intellectual-property foundation

TF Holding maintains a coordinated patent family filed at AGEPI, structured for international extension through the Paris Convention following Moldova's accession to the European Patent Convention on 1 June 2026.

See the full patent family overview →

Partner classes under early conversation

Three partner classes:

• Humanitarian and field-medicine operators
• Space-mission programmes (analog and commercial)
• Operators of isolated terrestrial environments (polar stations, deep-water vessels, offshore platforms, rural primary-care networks)

First commercial deployment path

The first commercial deployment is deliberately conservative: antimicrobial stewardship and structured physician-review packets in routine primary-care settings. Disciplined non-action — declining to prescribe where evidence does not support — and verifiable evidence of every clinical decision. From this conservative foundation, partnerships extend into the more demanding environments.